Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF)

• Published in: Journal of antimicrobial chemotherapy Vol. 64; no. 3; pp. 501 - 506
• Main Authors: Tazumi, Akihiro, Maeda, Yasunori, Goldsmith, Colin E., Coulter, Wilson A., Mason, Charlene, Millar, B. Cherie, McCalmont, Mark, Rendall, Jackie, Elborn, J. Stuart, Matsuda, Motoo, Moore, John E.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.09.2009; Oxford Publishing Limited (England)
• Subjects: Adult; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; antibiotic resistance; Antibiotics; Antibiotics. Antiinfectious agents. Antiparasitic agents; azithromycin; Azithromycin - therapeutic use; Bacterial Proteins - genetics; Biological and medical sciences; commensal; Cystic fibrosis; Cystic Fibrosis - complications; Cystic Fibrosis - drug therapy; DNA, Bacterial - chemistry; DNA, Bacterial - genetics; Drug resistance; Drug Resistance, Bacterial; Errors of metabolism; erythromycin; Erythromycin - pharmacology; Humans; Macrolides - pharmacology; Medical sciences; Membrane Proteins - genetics; Metabolic diseases; Methyltransferases - genetics; Microbial Sensitivity Tests; Miscellaneous hereditary metabolic disorders; Molecular biology; Molecular Sequence Data; Pharmacology. Drug treatments; Sequence Analysis, DNA; Streptococcal Infections - microbiology; Streptococcus - drug effects; Streptococcus - genetics; Streptococcus - isolation & purification; Streptococcus anginosus; Streptococcus australis; Streptococcus gordonii; Streptococcus infantis; Streptococcus infections; Streptococcus mitis; Streptococcus oralis; Streptococcus parasanguinis; Streptococcus pneumoniae; Streptococcus salivarius; Streptococcus sanguinis; azithromycin; commensal; antibiotic resistance; erythromycin; Human; Treatment resistance; Nucleotide sequence; Respiratory disease; Azithromycin; Metabolic diseases; Cystic fibrosis; Erythromycin; Macrolide; Genetic disease; Streptococcus pneumoniae; Streptococcaceae; Antibiotic; Bacteria; Micrococcales; Digestive diseases; Adult; Protein synthesis inhibitor; Antibacterial agent; Clinical isolate; Pancreatic disease

Objectives Although long-term use of azithromycin has shown a significant clinical improvement for patients with cystic fibrosis (CF), its long-term effect on the susceptibility of commensal flora within CF airways has not yet been examined. We therefore suggest that long-term use of azithromycin in...